Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound
Summary
- Initiated a small position in Tevogen Bio Holdings Inc. due to a promising pipeline and favorable seasonal patterns, despite only one Wall Street analyst covering it.
- Tevogen Bio develops T-cell therapies for infectious diseases, cancers, and neurological disorders, with TVGN 489 completing Phase 1 trials for Long COVID and COVID-19.
- The stock has experienced significant price fluctuations, with lows likely due to tax loss selling and potential upside from the Santa Claus Rally and January effect.
- Reverse merger with Semper Paratus Acquisition Corporation, high insider ownership, and a $4.20 price target suggest potential upside, justifying a small, speculative investment.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of TVGN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.